Data across large BC clinical trials supported that the high levels of tumor-infiltrating lymphocytes (TILs) are predictive biomarkers for favorable prognosis and of the response to immunotherapy, particularly in HER-2+ BC and TNBC (5). This evidence concerns the gene ERBB2 and neoplasm.